Correlation between plasma lipoprotein-associated phospholipase A2 levels and risk of ischaemic stroke recurrence by gender in the Chinese population

References

• Lee J, Phillips D, Wilkens J, et al. Cross-country comparisons of disability and morbidity: evidence from the gateway to global aging data. J Gerontol A Biol Sci Med Sci. 2018;73(11):1519–1524. doi: 10.1093/gerona/glx224
   PubMed Web of Science ®Google Scholar
• Dhamoon MS, Sciacca RR, Rundek T, et al. Recurrent stroke and cardiac risks after first ischemic stroke: the Northern Manhattan Study. Neurology. 2006;66(5):641–646. doi: 10.1212/01.wnl.0000201253.93811.f6
   PubMed Web of Science ®Google Scholar
• Lekoubou A, Nkoke C, Dzudie A, et al. Recurrent stroke and early mortality in an urban medical unit in Cameroon. J Stroke Cerebrovasc Dis. 2017;26(8):1689–1694. doi: 10.1016/j.jstrokecerebrovasdis.2017.03.031
   PubMed Web of Science ®Google Scholar
• Bergström L, Irewall AL, Söderström L, et al. One-year incidence, Time Trends, and predictors of recurrent ischemic stroke in Sweden from 1998 to 2010: an observational study. Stroke. 2017;48(8):2046–2051. doi: 10.1161/STROKEAHA.117.016815
   PubMed Web of Science ®Google Scholar
• Nam KW, Kwon HM, Lim JS, et al. Clinical relevance of abnormal neuroimaging findings and long-term risk of stroke recurrence. Eur J Neurol. 2017;24(11):1348–1354. doi: 10.1111/ene.13391
   PubMed Web of Science ®Google Scholar
• Clark K, Sharp S, Womack CJ, et al. Increased sedentary time and decreased physical activity increases lipoprotein associated phospholipase A(2) in obese individuals. Nutr Metab Cardiovasc Dis. 2022;32(7):1703–1710. doi: 10.1016/j.numecd.2022.04.023
   PubMed Web of Science ®Google Scholar
• Zhang S, Huang S, Hu D, et al. Biological properties and clinical significance of lipoprotein-associated phospholipase A(2) in ischemic stroke. Cardiovasc Ther. 2022;2022:1–12. doi: 10.1155/2022/3328574
   Web of Science ®Google Scholar
• Shi Y, Zhang P, Zhang L, et al. Role of lipoprotein-associated phospholipase A2 in leukocyte activation and inflammatory responses. Atherosclerosis. 2007;191(1):54–62. doi: 10.1016/j.atherosclerosis.2006.05.001
   PubMed Web of Science ®Google Scholar
• Cohen JF, Korevaar DA, Altman DG, et al. STARD 2015 guidelines for reporting diagnostic accuracy studies: explanation and elaboration. BMJ Open. 2016;6(11):e012799. doi: 10.1136/bmjopen-2016-012799
   PubMed Web of Science ®Google Scholar
• Sacco RL, DeRosa JT, EC H Jr, et al. Glycine antagonist in neuroprotection for patients with acute stroke: GAIN Americas: a randomized controlled trial. JAMA. 2001;285(13):1719–1728. doi: 10.1001/jama.285.13.1719
   PubMed Web of Science ®Google Scholar
• Elkind MS, Tai W, Coates K, et al. High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med. 2006;166(19):2073–2080. doi: 10.1001/archinte.166.19.2073
   PubMedGoogle Scholar
• Wei L, Ke Z, Zhao Y, et al. The elevated lipoprotein-associated phospholipase A2 activity is associated with the occurrence and recurrence of acute cerebral infarction. Neuroreport. 2017;28(6):325–330. doi: 10.1097/WNR.0000000000000765
   PubMed Web of Science ®Google Scholar
• Dash P, Singh VK, Gautam D, et al. Aspirin resistance and blood biomarkers in predicting ischemic stroke recurrence: an exploratory study. Brain Circ. 2022;8(1):31–37. doi: 10.4103/bc.bc_75_21
   PubMedGoogle Scholar
• Lin J, Zheng H, Cucchiara BL, et al. Association of Lp-PLA2-A and early recurrence of vascular events after TIA and minor stroke. Neurology. 2015;85(18):1585–1591. doi: 10.1212/WNL.0000000000001938
   PubMed Web of Science ®Google Scholar
• Kim K, Lee JH. Risk factors and biomarkers of ischemic stroke in cancer patients. J Stroke. 2014;16(2):91–96. doi: 10.5853/jos.2014.16.2.91
   PubMed Web of Science ®Google Scholar
• Cestari DM, Weine DM, Panageas KS, et al. Stroke in patients with cancer: incidence and etiology. Neurology. 2004;62(11):2025–2030. doi: 10.1212/01.WNL.0000129912.56486.2B
   PubMed Web of Science ®Google Scholar
• Li X, Xu L, Xu Z. The diagnostic and prognostic performance of Lp-PLA2 in acute ischemic stroke. Med Clin. 2021;156(9):437–443. doi: 10.1016/j.medcli.2020.11.034
   PubMed Web of Science ®Google Scholar
• Chen C, Zhu J, Deng X, et al. Severe periodontitis is associated with the serum levels of hypersensitive C reactive protein and lipoprotein-associated phospholipase A2 in the patients of acute ischemic stroke. J Clin Neurosci. 2021;88:232–236. doi: 10.1016/j.jocn.2021.04.007
   PubMed Web of Science ®Google Scholar
• Brilakis ES, Khera A, McGuire DK, et al. Influence of race and sex on lipoprotein-associated phospholipase A2 levels: observations from the Dallas heart study. Atherosclerosis. 2008;199(1):110–115. doi: 10.1016/j.atherosclerosis.2007.10.010
   PubMed Web of Science ®Google Scholar
• Kernan WN, Brass LM, Viscoli CM, et al. Estrogen after ischemic stroke: clinical basis and design of the Women’s estrogen for stroke trial. J Stroke Cerebrovasc Dis. 1998;7(1):85–95. doi: 10.1016/S1052-3057(98)80026-8
   PubMedGoogle Scholar
• Tuttolomondo A, Pedone C, Pinto A, et al. Predictors of outcome in acute ischemic cerebrovascular syndromes: the GIFA study. Int J Cardiol. 2008;125(3):391–396. doi: 10.1016/j.ijcard.2007.03.109
   PubMed Web of Science ®Google Scholar
• Kazmierski R, Guzik P, Ambrosius W, et al. Predictive value of white blood cell count on admission for in-hospital mortality in acute stroke patients. Clin Neurol Neurosur. 2004;107(1):38–43. doi: 10.1016/j.clineuro.2004.03.003
   PubMed Web of Science ®Google Scholar
• Davì G, Tuttolomondo A, Santilli F, et al. CD40 ligand and MCP-1 as predictors of cardiovascular events in diabetic patients with stroke. J Atheroscler Thromb. 2009;16(6):707–713. doi: 10.5551/jat.1537
   PubMed Web of Science ®Google Scholar
• Wang WY, Li J, Yang D, et al. OxLDL stimulates lipoprotein-associated phospholipase A2 expression in THP-1 monocytes via PI3K and p38 MAPK pathways. Cardiovasc Res. 2010;85(4):845–852. doi: 10.1093/cvr/cvp367
   PubMed Web of Science ®Google Scholar
• Paapstel K, Kals J, Eha J, et al. Inverse relations of serum phosphatidylcholines and lysophosphatidylcholines with vascular damage and heart rate in patients with atherosclerosis. Nutr Metab Cardiovasc Dis. 2018;28(1):44–52. doi: 10.1016/j.numecd.2017.07.011
   PubMed Web of Science ®Google Scholar
• Tuttolomondo A, Di Raimondo D, Pecoraro R, et al. HLA and killer cell immunoglobulin-like receptor (KIRs) genotyping in patients with acute ischemic stroke. J Neuroinflammation. 2019;16(1):88. doi: 10.1186/s12974-019-1469-5
   PubMed Web of Science ®Google Scholar
• Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25(5):923–931. doi: 10.1161/01.ATV.0000160551.21962.a7
   PubMed Web of Science ®Google Scholar
• Keleşoğlu M, Kızılay F, Barutçuoğlu B, et al. The relationship between lipoprotein-associated phospholipase A2 with cardiovascular risk factors in testosterone deficiency. Turk J Urol. 2018;44(2):103–108. doi: 10.5152/tud.2017.30633
   PubMed Web of Science ®Google Scholar
• Nègre-Salvayre A, Augé N, Camaré C, et al. Dual signaling evoked by oxidized LDLs in vascular cells. Free Radic Biol Med. 2017;106:118–133. doi: 10.1016/j.freeradbiomed.2017.02.006
   PubMed Web of Science ®Google Scholar
• Koenig W, Khuseyinova N, Löwel H, et al. Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110(14):1903–1908. doi: 10.1161/01.CIR.0000143377.53389.C8
   PubMed Web of Science ®Google Scholar
• Packard CJ, Reilly DS, Caslake MJ, et al. Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343(16):1148–1155. doi: 10.1056/NEJM200010193431603
   PubMed Web of Science ®Google Scholar
• May HT, Horne BD, Anderson JL, et al. Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J. 2006;152(5):997–1003. doi: 10.1016/j.ahj.2006.01.011
   PubMed Web of Science ®Google Scholar
• Koenig W, Twardella D, Brenner H, et al. Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 2006;26(7):1586–1593. doi: 10.1161/01.ATV.0000222983.73369.c8
   PubMed Web of Science ®Google Scholar
• Elkind MS, Leon V, Moon YP, et al. High-sensitivity C-reactive protein and lipoprotein-associated phospholipase A2 stability before and after stroke and myocardial infarction. Stroke. 2009;40(10):3233–3237. doi: 10.1161/STROKEAHA.109.552802
   PubMed Web of Science ®Google Scholar